Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gilead 4Q Revenues up 26% | Contract Pharma

What are you searching for?

Sign in
Financial News

Gilead 4Q Revenues up 26%

Revenue growth for the quarter and full year was primarily due to the launch of Veklury (remdesivir).

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead
4Q Revenues: $7.4 billion (+26%)
4Q Earnings: $1.5 billion (-43%)
YTD Revenues: $24.7 billion (+10%)
YTD Earnings: $123 million (earnings were $5.4 billion FY19)
Comments: Revenue growth for the quarter and full year was primarily due to the launch of Veklury (remdesivir) in 2020. Product sales excluding Veklury for the quarter and full year 2020 decreased 7% and 3%, respectively, due to the continued effects of COVID-19 on Gilead’s HIV and hepatitis C virus franchises, as well as the expected decline in sales of Truvada and tenofovir disoproxil fumarate-based products due to the loss of exclusivity of Truvada and Atripla in the U.S. in October 2020. Veklury sales were $1.9 billion and $2.8 billion, for the quarter and full year, respectively, reflecting higher hospitalization and treatment rates due to the most recent COVID-19 surge. HIV product sales were down 7% to $4.3 billion in the quarter, and up 3% to $16.9 billion for the year. HCV product sales were down 33% to $423 million in the quarter and 30% to $2.1 billion for the year. R&D expenses for the quarter and full year increased 44% to $1.6 billion, and 24% to $5 billion, respectively.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters